NJ News (4/22, Dearing) reports on epigenetics research efforts going on in New Jersey to help develop new medications for the treatment of Alzheimer’s. For example, “Princeton Medical Institute is the first study site in the United States to join a clinical trial for ORY-2001, a drug designed to slow cognitive decline and restore memory in patients with mild to moderate Alzheimer’s disease.” Should the experimental medicine be effective, “patients taking part in the study will have already received the drug rather than having to wait years for it to gain FDA approval and become available to the public. (SOURCE: APA Headlines)
- WHO Releases New Guidelines On How To Reduce Risk Of Dementia
- Physicians Define Type Of Dementia Similar To Alzheimer’s.
- Epigenetics Researchers In New Jersey Working To Develop New Medications For Alzheimer’s.
- Outpatient Treatment For Depression In The US Has Risen Steadily In Recent Decades, But To A Level Lower Than Expected, Study Indicates.
- Transcranial Magnetic Stimulation Helps Improve Memory In Older Adults, Study Suggests